PMID- 21809168
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20211020
IS  - 1433-8491 (Electronic)
IS  - 0940-1334 (Linking)
VI  - 262
IP  - 2
DP  - 2012 Mar
TI  - Descriptive analyses of the aripiprazole arm in the risperidone long-acting 
      injectable versus quetiapine relapse prevention trial (ConstaTRE).
PG  - 139-49
LID - 10.1007/s00406-011-0220-8 [doi]
AB  - A recent randomized, open-label, relapse prevention trial (ConstaTRE) compared 
      outcomes with risperidone long-acting injectable (RLAI) versus the oral atypical 
      antipsychotic quetiapine. This study also included a small descriptive arm in 
      which patients could also be randomized to aripiprazole. Results of this 
      exploratory analysis are described here. Clinically stable adults with 
      schizophrenia or schizoaffective disorder previously treated with oral 
      risperidone, olanzapine, or an oral conventional antipsychotic were randomized to 
      RLAI or aripiprazole. Efficacy and tolerability were monitored for up to 24 
      months. A total of 45 patients were treated with aripiprazole (10-30 mg/day) and 
      329 patients with RLAI (25-50 mg i.m. every 2 weeks). Relapse occurred in 27.3% 
      (95% CI: 15.0-42.8%) of aripiprazole-treated and 16.5% (95% CI: 12.7-21.0%) of 
      RLAI-treated patients. Kaplan-Meier estimates of mean (standard error) 
      relapse-free period were 313.7 (20.4) days for aripiprazole and 607.1 (11.4) days 
      for RLAI patients. Remission was achieved by 34.1% (95% CI: 20.5-49.9%) of 
      aripiprazole and 51.1% (95% CI: 45.5-56.6%) of RLAI patients. Clinical global 
      impression-change was improved ("minimally improved" to "very much improved") in 
      26.4% with RLAI and 15.9% with aripiprazole patients. Tolerability was generally 
      good for both treatment groups. Weight gain (7.0% with RLAI vs. 4.4% with 
      aripiprazole), extrapyramidal adverse events (AEs) (10.3% vs. 4.4%), and 
      potentially prolactin-related AEs (4.6% vs. 0%) were more common with RLAI 
      treatment, and gastrointestinal disorders were more common in 
      aripiprazole-treated patients (22.2% vs. 6.1%). Time-to-relapse in stable 
      patients with schizophrenia or schizoaffective disorder was numerically longer in 
      RLAI-treated patients than in aripiprazole-treated patients although not 
      statistically significant. Both treatments were generally well tolerated.
FAU - de Arce Cordon, Rosario
AU  - de Arce Cordon R
AD  - Servicio de Psiquiatria, Clinica Puerta de Hierro, Hospital Universitario Puerta 
      de Hierro, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain. 
      rarce.hpth@salud.madrid.org
FAU - Eding, Evelin
AU  - Eding E
FAU - Marques-Teixeira, Joao
AU  - Marques-Teixeira J
FAU - Milanova, Vihra
AU  - Milanova V
FAU - Rancans, Elmars
AU  - Rancans E
FAU - Schreiner, Andreas
AU  - Schreiner A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110802
PL  - Germany
TA  - Eur Arch Psychiatry Clin Neurosci
JT  - European archives of psychiatry and clinical neuroscience
JID - 9103030
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dibenzothiazepines)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 82VFR53I78 (Aripiprazole)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Aripiprazole
MH  - Dibenzothiazepines/adverse effects
MH  - Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Piperazines/therapeutic use
MH  - Psychotic Disorders/*drug therapy/*prevention & control
MH  - Quetiapine Fumarate
MH  - Quinolones/therapeutic use
MH  - Retrospective Studies
MH  - Risperidone/administration & dosage
MH  - Schizophrenia/*drug therapy/*prevention & control
MH  - Secondary Prevention
MH  - Time Factors
EDAT- 2011/08/03 06:00
MHDA- 2012/07/17 06:00
CRDT- 2011/08/03 06:00
PHST- 2010/12/07 00:00 [received]
PHST- 2011/05/18 00:00 [accepted]
PHST- 2011/08/03 06:00 [entrez]
PHST- 2011/08/03 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 10.1007/s00406-011-0220-8 [doi]
PST - ppublish
SO  - Eur Arch Psychiatry Clin Neurosci. 2012 Mar;262(2):139-49. doi: 
      10.1007/s00406-011-0220-8. Epub 2011 Aug 2.